Immunic, Inc. short interest in 2025
In 2025, Immunic, Inc.'s disclosed short interest ran from 3.91% of shares outstanding on 15 Jan 2025 to 5.46% on 31 Dec 2025, a change of +1.55 percentage points. The year's high was 10.58% on 30 Sep 2025 and its low 2.24% on 31 Mar 2025, averaging 6.04% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.83 days on 15 Jul 2025. Full history: Immunic, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 3.91% (15 Jan 2025)
- End of year
- 5.46% (31 Dec 2025)
- Change
- +1.55 pp
- High
- 10.58% (30 Sep 2025)
- Low
- 2.24% (31 Mar 2025)
- Average
- 6.04%
- Highest days to cover
- 10.83 (15 Jul 2025)
- SEC filings marked
- 6
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 3.91% | 3.71 | |
| 31 Jan 2025 | 4.17% | 2.93 | |
| 14 Feb 2025 | 2.83% | 5.41 | |
| 28 Feb 2025 | 2.66% | 1.91 | |
| 14 Mar 2025 | 2.57% | 3.92 | |
| 31 Mar 2025 | 2.24% | 3.40 | 10-K filed |
| 15 Apr 2025 | 2.30% | 3.03 | |
| 30 Apr 2025 | 3.04% | 1.88 | |
| 15 May 2025 | 2.85% | 2.48 | 10-Q filed |
| 30 May 2025 | 4.43% | 2.28 | |
| 13 Jun 2025 | 7.77% | 2.73 | |
| 30 Jun 2025 | 9.35% | 3.76 | |
| 15 Jul 2025 | 8.94% | 10.83 | |
| 31 Jul 2025 | 9.92% | 7.46 | |
| 15 Aug 2025 | 9.78% | 9.03 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 9.97% | 8.55 | |
| 15 Sep 2025 | 10.15% | 6.26 | |
| 30 Sep 2025 | 10.58% | 7.33 | |
| 15 Oct 2025 | 9.62% | 5.81 | |
| 31 Oct 2025 | 8.35% | 6.18 | |
| 14 Nov 2025 | 4.76% | 4.62 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 4.65% | 4.84 | |
| 15 Dec 2025 | 4.75% | 4.17 | |
| 31 Dec 2025 | 5.46% | 4.09 |
See also: Immunic, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.